Ucan, U. S.Yildirim, S.Simsek, A.Ortatatli, M.Erganis, O.2020-03-262020-03-2620070019-6479https://hdl.handle.net/20.500.12395/21726Transforming Growth Factor-beta(1) (TGF - beta(1))'s mitogenic activities have been documented to some extent in dentinogenesis and wound healing. However, TGF as a therapeutical agent has not been considered neither in veterinary nor in medical dentistry so far. In order to examine this, it is first necessary. to incorporate the cytokine to a slow delivery system and then to show its various effects on different types of cells. The present study was designed to evaluate the properties of two different adjuvants, aluminium hydroxide (AH) and calcium phosphate (CP), as delivery substances for recombinate human TGF-beta(1).eninfo:eu-repo/semantics/closedAccessArticle844356358WOS:000246643700007Q4